

Response to Reviewers

"The authors should include a representative figure for this paper in order to improve the readability of the text. Please provide. - the authors should include a table gathering the main findings from literature about all of the clinical fields of application of Thymosin. Specifically, they should distinguish between preclinical and clinical studies. Please provide. - the authors include COVID-19 referral into two section of the manuscript. This is redundant. Please delete the section dedicated to COVID-19 into the "CLINICAL AND COMMERCIAL APPLICATIONS" paragraph."

The reviewer's comments are as listed above.

Changes made in this revision include:

1. Grammatical corrections to the entire paper
2. Removal of unnecessary or redundant sections.
3. Creation of figures to improve readability.

Specific Comments To Authors:

This comprehensive review is very interesting but it must be noticed that the use of thymosine alpha in the treatment of viral hepatitis B and C is now obsolete so the authors must be mentioned in the review that was used only in the era of interferon before the discovery of the new direct antiviral agents (DAAs) to avoid confusion of the readers.

Answer:

We would like to thank each of the editors involved in working on this manuscript. It has been an excellent process with very clear goals and endpoints. We appreciate all of

the effort put in. Please find attached with this comment our revised manuscript with edits made to the section involving Hepatitis. All edits have been highlighted.